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Methods: VSMC grown in serum free media for 48hours were co-cultured with mono- 
cytes (M) for 72hours, in the presence of M-CSF or ILI~. The apoptotic index was mea- 
sured using an established apoptosis assay. M-CSF and ILI~ were used at 
concentrations of t00ng/ml and 100pg/ml to lng,'ml, respectively. Apprepriate controls 
were set up for all experiments. 
Resulte: ILl~ at physiological concentrations (100pg/ml) did not increase VSMC apopto- 
sis (10.5±2.4%); this was similar to control VSMC with M alone, whereas M-CSF-acti- 
vated M significantly increased VSMC apoptosis (60.0+-3.0%, p< 0.008). 
Suprephysiological doses of ILI~ (500pg and lng/ml) did cause an increase in mono- 
cyte-induced killing of VSMC (59.5+ 3.5% and 59.0-J: 3.8% respectively). However, such 
effect was shown to be mediated by endogenous production of M-CSF upon ILI~ stimu- 
lation. Thus, VSMC co-cultured with M and tL113 (500pg and 1 ng/ml) were pretreated with 
an anti M-CSF neutralizing antibody (lp.g/ml). The VSMC apoptosis was nearly abro- 
gated in the presence of the anti M-CSF mAb (17.0± 2.1% and 13.6±1.9%, p_<0.007 and 
p_<0.005 respectively), when compared to VSMC co-cultured with M-CSF activated M 
alone. A nonspecific isotype control (IgG2a) was used and did not block the ILl (lng/ml) 
induced VSMC apoptosis (55.0±2.0%). Conclusions; M-CSF could function as an 
important rate limiting eytokine in the process of activated monocyte induced killing of 
VSMC, suggesting a final common pathway for atheroma plaque destabUization. 
11:30 a.m. 
853-5 Arterial Injury in ApoE -/- and C57/BL6 Wild Type Mice: 
Evidence for Macrophage Apoptosis as a Mechanism 
Regulating Tissue-Factor Expression and Plaque 
Growth 
Randolph Hutter. Juan J. Badimon, Bernhard V. Sauter, John T. Fallon, Valentin Fuster, 
Cardiovascular Institute. Mount Sinai Medica/ Center, New York, New York. 
Background: Macrophages undergoing apoptosis are considered contributing to pro- 
gression of athereoscleretic lesions. Tissue factor is a key cell-mediated activator of extrin- 
sic coagulation-cascede and can induce thrombus formation. 
Methods: In the present study, we examined the role of macrophage apoptosis on 
plaque growth by comparing neointima formation in ApoE -/- (n=10) and C57/BL 6 wild 
type mice (n=23) in a model of femoral arterial denudation injury. 
Results: Arterial injury resulted in significantly increased neointima formation in ApoE -/- 
mice at 4 weeks compared to wild type mice (4.84 ± 1.26 mm 2 x 10 .2 vs. 0.73 ± 0.03 
mm 2 x 10"2; P<0.01). Apoptotic macrophages and foam cells as detected by cespase*3 
expression, characteristic morphology and positive staining for MOMA-2 were found only 
in lesions of ApoE -/- mice and accounted for up to 33 ± 6 % of intimal cells at 4 weeks 
after arterial injury compared to less than 0.5 % apoptotic ells in neointima of wild type 
mice (P<0.01). Importantly, neointima size significanly correlated with the content of apo- 
ptotic macrophages in neointima (r=0.64, P<0.01). In addition, apoptotic macrophages 
were directly associated with increased cellular tissue factor expression (r=0.97, P<0.01) 
as well as reduced alpha-actin expression (r=-0.75, P<O.01) in neointima of ApoE -/- 
mice. 
Conclusions: Apoptosis of maerophages and enhanced expression of cellular tissue 
factor in neointima correlated with increased plaque growth and change of neointima to 
an unstable plaque-like phenotype. These findings point to an important role of pro- 
grammed cell death occuring in macrophages in modulating arterial esion biology and 
controlling thrombogenie properties of intimal lesions following arterial injury. 
11:45 a.m. 
853-6 Asymmetric Dimethylarginine Stimulates the 
Expression of Matrix Metalloproteinase-9 in Human 
Monocytes via Tumor Necrosis Factor-a 
Euv-Mvouno Jeono. Sungyoul Hong, Jeong-Euy Park, Samsung Medica/Center, 
Sungkyunkwan University School of Medicine, Seoul, South Korea, Center for Clinical 
Research, Samsung Biomedical Research Institute, South Korea. 
Background: Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibi- 
tor of nitric oxide synthase, has recently been reported as an atherogenic molecule. 
ADMA induces the endothelial dysfunction and influences the monocyte adhesion to the 
endothelial cells. We tried to investigate whether ADMA induces the release of proinflem- 
matory cytokines and the expression of matrix metalloproteinase-9 (MMP-9), 
Methods: Human monocytic ell line, THP-1 was incubated with ADMA (0.1 - 10 pM) in 
a time-dependent manner and supernatants were harvested for the detection of proin- 
flammatory cytokines by ELISA. The expression of MMP-9 by ADMA was determined by 
gelatin-zymography and northern hybridization. 
Resulte: Tumor necrosis factor (TNF)-c~ was released at about 800 pg/ml within 12 h, 
whereas interleukin (IL)-6 was not. ADMA also stimulated the expression of monocytic 
chemotatic factors such as IL-8 and monocyte chemoattractant protein (MCP)-I. No 
effects were detected by symmetric dimethylarginine and N-monomethylarginine. ADMA 
induced the secretion of MMP-9 in a dose-dependent manner. To determine whether 
TNF-~ mediated MMP-9 up-regulation, anti-TNF-c( monoclonal antibodies were co-incu- 
bated with ADMA to block the action of TNF-~. Anti-TNF-~ monoclonal antibody blocked 
completely the induction of MMP-9 by ADMA. Conclusion: This study suggests that 
ADMA induces the release of proinflammatory c tokines, TNF-c~, IL-8 and MCP-1 in 
monocytes. The up-regulation of MMP-9 is mediated by TNF-c~ in ADMA treated mono- 
cytes. These findings provide the evidences that ADMA may be involved in the plaque 
formation and instabilization i atherosclerosis. 
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1176-69 Effects of Low Dose Hormone Replacement Therapy on 
Nitric Oxide BioacUvity and Markers of Inflammation 
Compared With Conventional Dose in Poetmenopauaal 
Women 
Kwano K. Koh. Mi-Seung Shin, Gachon Medical School, Incheon, South Korea. 
Background: We have previously shown that conventional dose hormone replacement 
therapy (C-HRT) improved nitric oxide (NO) bioactivity and reduced markers of inflam- 
mation in postmenopausal women (PMW). The effects of low-dose hormone replace- 
ment herapy (L-HRT) has not yet observed. 
Methods: We administered micronized progesterone (MP) 100 mg with conjugated 
equine estrogen (CEE) 0.025 (C-HRT) or 0.3 (L-HRT) mg daily for 2 months to 15 PMW 
with a washout period of 2 months in a randomized, double-blind, crossover study. Data= 
meani¾SD. *=P<0.01, **=P<0.001 vs. Baseline. 
Results: L-HRT and C-HRT significantly changed lipoprotein levels. L-HRT improved 
flow-mediated ilation (FMD) and tended to reduce plasma E-selectin, but not VCAM-1, 
CRP and fibrinogen levels compared with respective basetine levels. However, there 
were no significant differences between L-HRT and C-HRT regarding these effects. 
There were no significant correlations between absolute levels or pement changes of 
CRP levels and absolute levels or percent changes of FMD or E-selectin (all riA0.155). 
Conclusion: L-HRT has comparable ffects to C-HRT in PMW regarding lipoproteins, 
FMD, and markers of inflammation. 
Baseline1 C-HRT Baseline2 L-HRT 
FMD (%) 4 .80+1.26  7.14+1.75"* 4.93+1.23 6.40+-1.64"* 
E-selectin 41±9 37±10" 39~8 37+9 
VCAM-1 468±172 484±179 464+-175 442+168 
CRP 0.26_+0.21 0.30-~'0.31 0 .19±0.15  0.19-Z0.09 
1176-71 Cyclosporine-lnduced Hypertension and Vascular 
Superoxide Production 
Joseeh N. Graziano, Carolyn L. Buller, John R. Charpie, University of Michigan, Ann 
Arbor, Michigan. 
Background: Cyclospodne A (CSA)-induced endothelial dysfunction and systemic 
hypertension contribute to significant morbidity and mortality following orthotopic heart 
transplantation. Several experimental models of hypertension have recently been linked 
with endothelial dysfunction and increased vascular oxidant stress. We hypothesize that 
CSA increases vascular superoxide (02-) production leading to a decrease in bioavail- 
able nitric oxide, an endogenous vasodilator. 
Methods: Adult male C57BL/6J mice (age 8-10 weeks) were treated for 12 days with 
either CSA (25 mg/kg in olive oil via intrapedtoneal injection; n=12), vehicle (n=5), 1 mM 
Tempol (a superoxide dismutase mimetic administered in the drinking water; n=5) or CSA 
+ Tempol (n=5). Systolic blood pressure (SBP) was measured aily by tail cuff method. 
Additionally, cultured human umbilical vein endothelial cells (HUVEC) were grown to con- 
fiuecce and incubated in phosphate buffered saline with 0.1 pM CSA (or ethanol vehicle) 
for ten minutes. Superoxide production was measured (n=4) by lucigenin-dedved chemi- 
luminescence (5 p.M). 
Results: CSA administration resulted in a significant increase in SBP from 113+5 mmHg 
(mean ± SEM) pretreatment to 184±2 mmHg on day 12 (p<0.0001). In contrast, co- 
administration of Tempol with CSA completely inhibited the CSA-induced increase in 
SBP (111±2 mmHg on day 12). Neither vehicle nor Tempol alone had any effect on SBP. 
Incubation of HUVEC with CSA resulted in a 15+1% increase in 02- production com- 
pared to HUVEC alone (p=0.02). Incubation of HUVEC with the endothelial nitric oxide 
synthase inhibitor N~°-monomethyl L-arginine (L-NMMA, 1raM) resulted in an 11+_2% 
increase in 02" production (p=0.04). Furthermore, there was a synergistic response to L- 
NMMA and CSA with an 85+_10% increase in 02" production compared to HUVEC alone 
(p<0.001). Tempol (1raM) completely inhibited the increase in 02" in both CSA and CSA 
+ L-NMMA treated cells. 
Conclusions: CSA treatment increases blood pressure and endothelial cell 02" produc- 
tion. Inhibition of nitric oxide production augments the increase in CSA-induced 02" pro- 
duction, suggesting that excess 02" may scavenge nitric oxide and decrease its 
bioavailability. 
